Biomarker Testing 2026: Which Tests to Get for Lung, Breast, Colorectal, and Prostate Cancers

Biomarker testing looks for genes, proteins, mutations, or other cancer-related signals that may influence treatment decisions. These tests may be done on tumor tissue, blood samples, or sometimes both, depending on the cancer type and stage.

Patients searching for biomarker testing in Hyderabad should understand that these tests are not the same as routine blood tests. They require oncologist guidance, reliable laboratory methods, and careful interpretation alongside biopsy reports, scans, symptoms, and treatment goals.

In non-small cell lung cancer, biomarker testing is especially important because several targeted therapies are available for specific mutations. Commonly tested markers may include EGFR , ALK , ROS1 , BRAF , MET , RET , NTRK , HER2 , KRAS , and PD-L1 .

For advanced lung cancer, comprehensive next-generation sequencing may be preferred when available, because it can detect multiple actionable changes from one sample. Patients looking for lung cancer biomarker testing in Hyderabad should ask whether tissue testing, liquid biopsy, or both are appropriate.

Breast cancer biomarker testing usually begins with ER , PR , and HER2 testing. These markers help classify breast cancer and guide hormone therapy, HER2-targeted therapy, chemotherapy, and other treatment decisions.

In selected patients, additional tests may include BRCA1/BRCA2 , PIK3CA , ESR1 , PD-L1 , and genomic recurrence-risk assays, depending on cancer stage and subtype. Patients seeking precision oncology care in Hyderabad should discuss which tests are useful for early-stage versus metastatic breast cancer.

For colorectal cancer, important biomarkers may include KRAS , NRAS , BRAF , MSI-H/dMMR , HER2 , and sometimes NTRK . These results can influence decisions about targeted therapy, immunotherapy, and treatment sequencing.

For prostate cancer, biomarker testing may include BRCA1 , BRCA2 , other homologous recombination repair genes, MSI-H/dMMR , and selected genomic tests in advanced disease. Patients exploring advanced cancer diagnostics in Hyderabad should ask whether germline genetic testing is also needed for family risk assessment.

Not every patient needs every biomarker test. Testing decisions depend on cancer type, stage, biopsy quality, previous treatments, family history, treatment availability, and clinical urgency. A qualified medical oncologist can help choose the most relevant test panel.

Useful questions include:

• Which biomarkers are recommended for my cancer type?
• Should testing be done on tissue, blood, or both?
• Will the result change my treatment plan?
• Is genetic counselling needed for inherited cancer risk?
• How long will results take?

According to Dr Nishith Vaddeboina , “Biomarker testing is valuable only when it is linked to a clear clinical decision. The goal is not to order the largest test panel, but to identify information that can safely guide personalised treatment.”

Biomarker testing in 2026 is an important part of modern cancer care for lung, breast, colorectal, and prostate cancers. These tests can help identify targeted therapy options, immunotherapy suitability, inherited cancer risks, and clinical trial opportunities in selected patients.

If you would like to understand which biomarker tests are appropriate for your diagnosis, consult Dr Nishith Vaddeboina , Medical Oncologist in Hyderabad, for personalised guidance based on your cancer type, stage, reports, and treatment goals.

Book a consultation with Dr Nishith Vaddeboina , Medical Oncologist in Hyderabad, to discuss which biomarker tests may help guide your personalised cancer treatment plan.